In a collaborative project with Prof. David A. Jans, Professor, of Biochemistry and Molecular Biology, Monash University we are studying Plasmodium falciparum and Toxoplasma gondii importin alpha proteins as potential drug targets. This project addresses an early stage of drug discovery for globally prevalent infectious diseases.
Plasmepsins are aspartic proteases found P. falciparum, and they have homologs in T. gondii as well. In a collaborative project with Prof. Prasenjit Bhaumik, Dept. of Biosciences & Bioengineering IIT Bombay, we are studying the in vivo effects of mechanism based inhibitors against these parasite aspartic proteases that have been designed in his lab.
Translational regulation is an important feature of apicomplexan parasites. In a collaborative project with Prof. Sandip Kaledhonkar, Dept. of Biosciences & Bioengineering IIT Bombay, we are studying the structures of proteins that interact with parasite ribosomes, potentially acting as reinitiation factors.
In a project with Prof. Sanjeeva Srivastava, Department of Biosciences and Bioengineering IIT Bombay, proteomics analyses of samples from malaria patients are being used for discovery of novel prognostic biomarkers for severe malaria.
The major challenges in treatment of this disease are the emerging drug resistance and the prognosis of severe malaria. Identification of prognostic biomarkers for severe malaria is needed for early disease detection. Prof. Srivastava brings his expertise in proteomics based expression profiling of serum of patients suffering from P. falciparum and P. vivax malaria infection. Clinical samples for this research are obtained from different parts of India.
This project is a collaboration with researchers at the International Center for Excellence in Malaria Research (ICMER, funded by the US National Institute of Health), Goa Medical College, and IIT Bombay. We work with Prof. Pradipsinh Rathod's laboratory at University of Washington, Seattle and Prof. Manoj Duraisingh's laboratory at the Harvard School of Public Health, Boston.